Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Pfizer's second-quarter results were better than expected. The drugmaker will still face some near-term uncertainty. However, its long-term prospects look attractive, especially at current levels.